• Ceftolozane/Tazobactam: Expanding β-Lactam Options for Resis

  2026-06-19

  The reference study reviews ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor combination, focusing on its enhanced activity against multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. Its unique pharmacodynamics and clinical trial data mark a significant advancement for researchers investigating antibacterial agents targeting resistant pathogens.

• Complexation of Mianserin HCl with DM-β-CD: Impact on Cytoto

  2026-06-19

  This study investigates how complexing Mianserin Hydrochloride with heptakis (2,6-di-O-methyl)-β-cyclodextrin (DM-β-CD) alters its cytotoxicity profile. The findings reveal that, unlike native β-cyclodextrin, DM-β-CD increases the cytotoxicity of mianserin in cell-based assays, underscoring the nuanced effects of cyclodextrin derivatives on drug behavior and safety.

• G-15: Unlocking GPR30 Antagonism for Translational Advances

  2026-06-18

  This article offers a strategic, mechanistic, and evidence-based perspective on harnessing G-15—a selective G protein-coupled estrogen receptor antagonist—for next-generation estrogen signaling research. By weaving together the latest mechanistic insights, experimental best practices, and translational opportunities, it provides translational researchers with a roadmap for leveraging GPR30 antagonism to dissect pain circuitry, cellular proliferation, and neuroendocrine mechanisms. Drawing upon recent findings in neuropathic pain and competitive product intelligence, this piece clarifies how G-15 from APExBIO enables rigorous, high-specificity interrogation of non-classical estrogen pathways, and highlights best-in-class protocols for robust, reproducible outcomes.

• DiscoveryProbe Metabolism-related Compound Library: Rational

  2026-06-18

  The DiscoveryProbe™ Metabolism-related Compound Library enables high-fidelity metabolic pathway interrogation with 493 bioactive compounds. This resource empowers reproducible metabolic enzyme inhibition assays and pathway elucidation, supporting advanced research in metabolic diseases and cancer biology.

• 20-HETE, TRPV1, and MrgprA3+ Neurons: Mechanisms of Chronic

  2026-06-17

  This study reveals how the lipid mediator 20-HETE activates TRPV1 channels on MrgprA3+ sensory neurons, driving allokinesis—a touch-evoked itch—in chronic dermatitis models. The findings uncover a mechanistic link between peripheral metabolic changes and altered sensory neuron excitability, suggesting new molecular targets for the management of chronic itch.

• PGF2α/PTGFR Signaling in Endometrial Breakdown Regulated by

  2026-06-17

  This study illuminates the pivotal role of prostaglandin F2α (PGF2α) and its receptor PTGFR in mediating endometrial breakdown and vascular remodeling during menstruation, with hypoxia-inducible factor-1α (HIF-1α) as a key upstream regulator. Use of AL-8810, a selective PTGFR antagonist, provided functional evidence for the pathway and its therapeutic research implications.

• (Z)-4-Hydroxytamoxifen: Strategic Leverage in ER Modulation

  2026-06-16

  This thought-leadership article explores (Z)-4-Hydroxytamoxifen’s mechanistic power as an estrogen receptor modulator, with a focus on its translational value for breast cancer research. By integrating experimental validation, competitive benchmarking, and strategic protocol guidance, the piece advances the discourse beyond typical product summaries—clarifying how this compound’s selectivity, binding affinity, and antiestrogenic activity uniquely position it as a keystone in estrogen receptor signaling and preclinical oncology workflows.

• Belinostat (PXD101): Deep Dive into HDAC Inhibition for Tran

  2026-06-16

  Explore how Belinostat (PXD101) advances epigenetic cancer therapy by enabling nuanced, quantitative analysis of histone deacetylase inhibition. This article provides a unique perspective on integrating advanced in vitro metrics with translational assay design for improved preclinical decision-making.

• Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit

  2026-06-15

  The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit enables high-resolution separation of proteins and peptides in the 1–10 kDa range, which are not efficiently resolved with traditional Tris-glycine SDS-PAGE. This kit is intended for research applications focused on low molecular weight protein and peptide analysis and should not be used for diagnostic or clinical purposes.

• Mianserin HCl in Translational Assays: Mechanistic Depth & P

  2026-06-15

  Explore the advanced mechanistic insights and assay optimization strategies of Mianserin HCl, a leading 5-HT2 receptor antagonist. This article uniquely dissects core clinical findings and cross-domain research workflows for next-generation antidepressant and antipathogenic studies.

• Pioglitazone (SKU B2117): Advanced PPARγ Agonist Solutions

  2026-06-14

  This scenario-driven article provides practical, evidence-based guidance for biomedical researchers and lab technicians using Pioglitazone (SKU B2117) as a selective PPARγ agonist. Integrating recent literature and real-world assay challenges, it highlights protocol optimization, data interpretation, and vendor selection, establishing Pioglitazone as a reliable, reproducible tool for metabolic and inflammatory disease research.

• (S)-(+)-Dimethindene maleate: Protocols for M2 Antagonism St

  2026-06-13

  (S)-(+)-Dimethindene maleate is a selective M2 muscarinic and histamine H1 receptor antagonist designed for research into autonomic regulation, cardiovascular, and respiratory physiology. Its specificity helps eliminate confounding effects from non-M2 muscarinic subtypes in receptor signaling studies. This compound is not intended for diagnostic or clinical use, and its utility is constrained to receptor-focused pharmacological investigations.

• High-Throughput BBB Permeability Prediction Using LLC-PK1-MD

  2026-06-12

  This study establishes a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells with lysosomal trapping correction to predict CNS drug permeability. The approach demonstrates strong predictive accuracy for brain distribution, offering a streamlined platform for early-stage screening of brain-penetrant therapeutics.

• MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliu

  2026-06-12

  Unlock the full potential of MTT as an in vitro cell proliferation assay reagent with actionable protocol enhancements and troubleshooting insights. This article bridges bench science and translational research by highlighting workflow precision, real-world troubleshooting, and how recent discoveries in cancer biology can refine assay design.

• Z-VDVAD-FMK (SKU A1922): Optimizing Caspase-2 Inhibition Wor

  2026-06-11

  This article delivers scenario-driven, evidence-based guidance for biomedical researchers employing Z-VDVAD-FMK (SKU A1922) in apoptosis and cell viability assays. Drawing on real laboratory challenges and literature-backed solutions, it contextualizes best practices for protocol design, data interpretation, and vendor selection—ensuring robust, reproducible results.

15647 records 1/1044 page Next 12345 下5页 Last page